BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Avagimyan AA, Mkrtchyan LG, Kononchuk NB, Kaktursky LV, Agati L. Chemotherapy as a possible trigger for the myocardial lipomatosis development. Arter gipertenz 2022;27:706-712. [DOI: 10.18705/1607-419x-2021-27-6-706-712] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Antineoplastics. Reactions Weekly 2022;1936:75-75. [DOI: 10.1007/s40278-022-29272-x] [Reference Citation Analysis]
2 Avagimyan AA, Kakturskiy LV. Trimetazidine as a modifier of doxorubicin+cyclophosphamideinduced hyperdyslipidemia. SJCEM 2022;37:105-111. [DOI: 10.29001/2073-8552-2022-37-2-105-111] [Reference Citation Analysis]
3 Avagimyan AA. Influence of trimetazidine on myocardium energy balance during chemotherapy with doxorubicin and cyclophosphamide. Sibirskij nauchnyj medicinskij zhurnal 2022;42:41-46. [DOI: 10.18699/ssmj20220304] [Reference Citation Analysis]
4 Avagimyan A, Kaktursky L. CARDIOTOXICITY OF CYCLOPHOSPHAMIDE: CURRENT STATE OF THE PROBLEM. jecm 2022. [DOI: 10.52340/jecm.2022.03.14] [Reference Citation Analysis]